Quick Answer
Tarsus Pharmaceuticals, Inc. reported Net Income of -$66.42 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$66.42M | +42.5% |
| 2024 | -$115.55M | +15.0% |
| 2023 | -$135.89M | -118.9% |
| 2022 | -$62.09M | -349.1% |
| 2021 | -$13.83M | +48.4% |
| 2020 | -$26.81M | -474.1% |
| 2019 | -$4.67M | -254.1% |
| 2018 | -$1.32M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.59M | +46.3% | +38.1% |
| June 30, 2025 | -$20.34M | +38.9% | +19.0% |
| March 31, 2025 | -$25.12M | +29.7% | -7.3% |
| September 30, 2024 | -$23.42M | +40.2% | +29.6% |
| June 30, 2024 | -$33.29M | -5.9% | +6.8% |
| March 31, 2024 | -$35.73M | -52.6% | +8.7% |
| September 30, 2023 | -$39.15M | -73.9% | -24.6% |
| June 30, 2023 | -$31.42M | -447.2% | -34.2% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +42.5% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Tarsus Pharmaceuticals, Inc.’s net income has declined by 4935.5% (from -$1.32 million to -$66.42 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: